The role of immune deregulation and NGF dysmetabolism in the development of Alzheimer disease in individuals with Down syndrome - PROJECT SUMMARY/ABSTRACT Down syndrome (DS) is a developmental genetic condition caused by trisomy of human chromosome 211-6. DS occurs in approximately 1 in 600-1000 live births and affects more than 300,000 individuals in the USA. Neuropathological and clinical features of Alzheimer’s disease (AD) present early in life through the seventh decade in a predictable sequence of events, and include amyloid plaques, neurofibrillary tangles, nerve growth factor (NGF) dysmetabolism and cholinergic basal forebrain degeneration, CNS inflammation, and cognitive decline1-10. DS is an outstanding natural genetic model for the study of AD pathophysiology, AD biomarkers research and to conduct preventive clinical trials. Despite the molecular and genetic similarities between AD and DS, there exists a paucity of information on the biological mechanisms underlying the onset of cognitive decline in adults with DS. For this INCLUDE application, our overall goal is to investigate DS-specific pathophysiological mechanisms of AD and identify novel biomarkers within and outside of the AT(N) framework, with a special focus on immune and NGF dysregulation at different stages of AD pathology in DS by capitalizing on the ongoing highly successful collaboration between our teams: Jorge Busciglio (University of California, Irvine, USA), Claudio Cuello (McGill University, Montreal, Canada), Thomas Wisniewski (New York University, NY, USA) and Juan Fortea (Hospital of Sant Pau, Barcelona, Spain)7-9, 11, 12. We propose to test the central hypothesis that CNS inflammation and NGF metabolic dysfunction are early and key pathophysiological mechanisms leading to neurodegeneration, accelerated aging and cognitive decline in DS. As detailed below, we will utilize a novel approach combining unbiased discovery (transcriptomics and proteomics) (Aim 1) and targeted biomarker analyses (Aim 2), using multiple complementary model systems, to establish a model of the temporal relationship between immune and NGF dysregulation and AD-related neurodegenerative changes in persons with DS (Aim 3). This will be achieved by correlating our findings with AD pathology, related biofluidic and imaging biomarker data from among the largest well characterized, DS patient population found globally. We propose the following 3 aims: Aim 1: To elucidate the relationships between immune deregulation and NGF dysmetabolism with AT(N) hallmarks in the DS brain and in human trisomy 21 cortical cultures. Aim 2: To investigate the presence of immune dysregulation and NGF dysmetabolism markers in plasma and CSF and in extracellular vesicles derived from brain tissue, primary cultures and body fluids across the AD continuum in DS. Aim 3: To establish the temporal ordering of immune dysregulation and NGF dysmetabolism with respect to the AT(N) framework within a cohort of adults with DS assessed longitudinally with multimodal biomarkers. The comprehensive combination of neuropathological, cellular, and clinical studies using the same biomarkers will lead to a detailed characterization of the role of immune and trophic factor alterations in the development of AD pathology and associated cognitive decline in DS. Guided by the INCLUDE initiative goals, the results will inform future preventive trials and assist in the prediction of the onset and evolution of AD dementia and in the identification of potential novel biomarkers and therapeutic targets in this vulnerable population.
